BiotechTube

Nivolumab

Phase 1/2UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Breast Cancer

Conditions

Metastatic Breast Cancer

Trial Timeline

Aug 1, 2019 → Dec 1, 2022

NCT ID
NCT04061863

About Nivolumab

Nivolumab is a phase 1/2 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04061863. Target conditions include Metastatic Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Breast Cancer were approved

Approved (20) Terminated (8) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enfortumab VedotinAstellas PharmaApproved
✅EligardAstellas PharmaApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved

Hype Score Breakdown

Clinical
9
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04061863Phase 1/2UNKNOWN

Competing Products

20 competing products in Metastatic Breast Cancer

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
AbemaciclibEli LillyPre-clinical
26
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
SYNB1891 + AtezolizumabSynlogicPhase 1
11
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
40
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
32
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Induction therapyChugai PharmaceuticalPhase 2
42
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
35
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
35
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
GC33Chugai PharmaceuticalPhase 1
29
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44